180 related articles for article (PubMed ID: 9399014)
1. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Rolan P
Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
[TBL] [Abstract][Full Text] [Related]
2. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
Seaber EJ; Ridout G; Layton G; Posner J; Peck RW
Eur J Clin Pharmacol; 1997; 53(3-4):229-34. PubMed ID: 9476036
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of zolmitriptan (Zomig, 311C90).
Lipton RB; Stewart WF
Cephalalgia; 1997 Oct; 17 Suppl 18():53-9. PubMed ID: 9399017
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
5. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
Dixon RM; Meire HB; Evans DH; Watt H; On N; Posner J; Rolan PE
Cephalalgia; 1997 Oct; 17(6):639-46. PubMed ID: 9350383
[TBL] [Abstract][Full Text] [Related]
6. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
Peck RW; Seaber EJ; Dixon R; Gillotin CG; Weatherley BC; Layton G; Posner J
Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
[TBL] [Abstract][Full Text] [Related]
7. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
Seaber EJ; Peck RW; Smith DA; Allanson J; Hefting NR; van Lier JJ; Sollie FA; Wemer J; Jonkman JH
Br J Clin Pharmacol; 1998 Nov; 46(5):433-9. PubMed ID: 9833595
[TBL] [Abstract][Full Text] [Related]
8. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Schoenen J; Sawyer J
Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults.
Dixon R; Engleman K; Kemp J; Ruckle JL
J Child Adolesc Psychopharmacol; 1999; 9(1):35-42. PubMed ID: 10357516
[TBL] [Abstract][Full Text] [Related]
10. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
[TBL] [Abstract][Full Text] [Related]
11. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
[TBL] [Abstract][Full Text] [Related]
12. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
Edmeads JG; Millson DS
Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
[TBL] [Abstract][Full Text] [Related]
13. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
Ferrari MD
Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
Dixon R; Gillotin C; Gibbens M; Posner J; Peck RW
Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
[TBL] [Abstract][Full Text] [Related]
15. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.
Smith DA; Cleary EW; Watkins S; Huffman CS; Polvino WJ
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):301-5. PubMed ID: 9660035
[TBL] [Abstract][Full Text] [Related]
16. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
[TBL] [Abstract][Full Text] [Related]
17. The clinical pharmacokinetics of zolmitriptan.
Dixon R; Warrander A
Cephalalgia; 1997 Oct; 17 Suppl 18():15-20. PubMed ID: 9399013
[TBL] [Abstract][Full Text] [Related]
18. Zolmitriptan. Introduction.
Mathew N
Cephalalgia; 1997 Oct; 17 Suppl 18():1-3. PubMed ID: 9399011
[No Abstract] [Full Text] [Related]
19. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
Smith DA; Cleary EW; Watkins S; Huffman CS; Dilzer SC; Lasseter KC
J Clin Pharmacol; 1998 Aug; 38(8):685-93. PubMed ID: 9725543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
